Stock 002038 BEIJING SL PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Beijing SL Pharmaceutical Co., Ltd.

Equities

002038

CNE000001L31

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
8.61 CNY +2.74% Intraday chart for Beijing SL Pharmaceutical Co., Ltd. +3.61% -15.51%
Apr. 24 Beijing SL Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2023 CI
Apr. 23 Beijing SL Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2022 2023 2024 2025
Capitalization 1 13,510 8,445 10,469 8,845 -
Enterprise Value (EV) 1 12,253 8,445 10,469 8,845 8,845
P/E ratio 27.8 x 35.7 x - - -
Yield 1.52% - 1.47% 1.74% 1.86%
Capitalization / Revenue 6.66 x - 10.3 x 7.47 x 6.44 x
EV / Revenue 6.66 x - 10.3 x 7.47 x 6.44 x
EV / EBITDA 21,189,883 x - - - -
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book 2.81 x - 1.8 x 1.53 x 1.47 x
Nbr of stocks (in thousands) 1,027,350 1,027,350 1,027,350 1,027,350 -
Reference price 2 13.15 8.220 10.19 8.610 8.610
Announcement Date 2/27/20 4/25/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2022 2023 2024 2025
Net sales 1 2,030 - 1,018 1,184 1,373
EBITDA 637.6 - - - -
EBIT 560.9 - - - -
Operating Margin 27.63% - - - -
Earnings before Tax (EBT) 560.9 - - - -
Net income 486.8 234.4 - - -
Net margin 23.98% - - - -
EPS 0.4738 0.2300 - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share 2 0.2000 - 0.1500 0.1500 0.1600
Announcement Date 2/27/20 4/25/23 4/23/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 286.9 193.1 241.7 245.1 315 307 252
EBITDA - - - - - - - -
EBIT - - - - - - - -
Operating Margin - - - - - - - -
Earnings before Tax (EBT) - - - - - - - -
Net income 201.9 - - - - - - -
Net margin - - - - - - - -
EPS 0.2000 - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 4/25/23 8/24/23 10/25/23 4/23/24 4/23/24 - - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2022 2023 2024 2025
Net Debt - - - - -
Net Cash position 1,257 - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) 10.4% - 7.41% 5.4% 6.6%
ROA (Net income/ Total Assets) - - - 5% 6%
Assets - - - - -
Book Value Per Share 1 4.680 - 5.650 5.630 5.850
Cash Flow per Share 1 0.6500 - 0.4500 0.1800 0.2300
Capex 273 - - - -
Capex / Sales 13.44% - - - -
Announcement Date 2/27/20 4/25/23 4/23/24 - -
1CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.61 CNY
Average target price
12 CNY
Spread / Average Target
+39.37%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
BEIJING SL PHARMACEUTICAL CO., LTD. Stock Beijing SL Pharmaceutical Co., Ltd.
-15.51% 1.22B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 234B
NOVARTIS AG Stock Novartis AG
+4.71% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002038 Stock
  4. Financials Beijing SL Pharmaceutical Co., Ltd.